16 August 2018
Visiongain’s new report Pharma ADMET Testing Market 2017-2027: In Vitro, In Vivo, In Silico, Leading Developed Markets, Leading Emerging Markets, Leading Companies indicates that the pharma ADMET Testing market will see $11.64bn in spending in 2020.
The pharma ADMET testing market is estimated at $7.43bn in 2016 and is expected to grow at a CAGR of 12.32% in the first half of the forecast period. The market is expected to grow at a CAGR of 10.50% in the second half of the forecast period. In 2016, the largest sector of the market was in vitro testing, which accounted for 44.3% of the ADMET testing market.
The lead analyst of this report said “Revenues for the ADMET Testing market will continue to increase during the 2015-2027 period as drug developers focus on improving candidate selection. The market which was once dominated by in vivo and in vitro tests is steadily giving way to in silico methods as technological advances gain footing.
Growth will be driven by the drug development budget cuts and the push for better candidate selections. With an approximate 90% attrition rate in clinical development, drug developers are more inclined than ever to choose better candidates and avoid losing hundreds of millions of clinical trials.”
The 149-page report contains 100 charts that add visual analysis in order to explain the developing trends within the pharma ADMET Testing market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the pharma ADMET Testing market and its leading submarkets: In Vivo ADMET Testing, In Vitro ADMET Testing and In Silico ADMET Testing.
The 149-page report offers market forecasts for the leading regional and national markets: the US, Germany, France, The UK, Italy, Spain, Japan, China, Brazil, Russia, India, South Korea and RoW.
Moreover, our work discusses the leading companies in the pharma ADMET Testing market. Our study also includes SWOT and STEP analysis of this industry and market.
The report Pharma ADMET Testing Market 2017-2027: In Vitro, In Vivo, In Silico, Leading Developed Markets, Leading Emerging Markets, Leading Companies report will be of value to anyone who wants to better understand the pharma ADMET Testing market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the pharma ADMET Testing market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.
06 May 2021
Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.
05 May 2021
Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.
29 April 2021
Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.